A Phase IB/II Clinical Study to Assess the Safety, Tolerability and Preliminary Efficacy of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs CM 313 (Primary)
- Indications Aplastic anaemia
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
- 31 Jan 2025 New trial record